All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 28 January 2020, the Marketing Authorization Application (MAA) for KTE-X19, a chimeric antigen receptor (CAR) T-cell therapy, was fully validated by the European Commission for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Authorization is currently under evaluation by the European Medicines Agency (EMA).1
The MAA was based on encouraging data from the single arm, open-label, phase II ZUMA-2 trial (NCT02601313) evaluating the efficacy of KTE-X19 in subjects with R/R MCL. With a median follow-up of 12.3 months, the study demonstrated an overall response rate of 93%, with 67% of patients in complete response following a single infusion of KTE-X19.2
KTE-X19 is an investigational, autologous, anti-CD19 CAR T-cell therapy containing CD3ζ signaling and CD28 costimulatory domains.3 KTE-X19 has previously been granted Priority Medicines (PRIME) by the EMA, Breakthrough Therapy Designation by the U.S. Food & Drug Administration and is currently in phase I/II trials in acute lymphoblastic leukemia (NCT02614066), MCL (NCT04162756) and chronic lymphocytic leukemia (NCT03624036).
If approved, KTE-X19 will be the first CAR T-cell therapy for the treatment of MCL. Read coverage of results from the ZUMA-2 trial presented at the American Society of Hematology 2019 Annual Meeting & Exposition here.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox